Psychoactive Substance Abuse Screening in Skilled Nursing Facilities
GIA® conducts screening conversations at the bedside, in the activity room, or by landline from the resident’s room — fitting naturally into existing daily routines without adding to nursing workload.
Substance use disorders are common and chronically undertreated in the United States. The Substance Abuse and Mental Health Services Administration’s 2022 National Survey on Drug Use and Health found that 48.7 million Americans aged 12 or older had a past-year substance use disorder, and that 72.7% — approximately 35.4 million people — did not receive any treatment in either specialty or non-specialty settings. The treatment-receipt gap is sustained by detection-stage barriers (under-recognition in primary care), patient-side barriers (stigma, denial, low insight), and system-side barriers (limited specialty referral capacity). Standard primary-care screening tools (AUDIT, AUDIT-C, DAST-10, NIDA Quick Screen, TAPS) are validated and recommended but inconsistently administered in time-pressured encounters — Porter et al. (J Gen Intern Med 2023) estimated that primary-care providers would need 26.7 hours per day to deliver all guideline-recommended preventive, chronic-disease, and acute care to a representative 2,500-patient panel. The U.S. Preventive Services Task Force gives a Grade B recommendation for screening for unhealthy drug use in adults 18 and older when services for accurate diagnosis, effective treatment, and appropriate care can be offered or referred. Peer-reviewed speech biomarker research underlying GIA® reports AUC 0.845 for substance use disorder detection from natural conversation. CPT 99408 (15–30 minute structured screening and brief intervention) and CPT 99409 (>30 minute) cover SBIRT (Screening, Brief Intervention, and Referral to Treatment) billing.
Why Psychoactive Substance Abuse goes undetected in skilled nursing facilities
Licensed nurses manage 15-30 residents per shift. CNAs handle direct care for 8-12 residents. Time for proactive screening is virtually nonexistent. Psychoactive Substance Abuse symptoms are often subtle, progressive, and easily attributed to other factors in this care environment.
CMS Five-Star ratings directly tied to clinical outcomes and survey results
MDS assessments require documented screening for cognitive and behavioral conditions
Staffing ratios make proactive screening nearly impossible during shifts
F-Tag deficiencies for missed conditions carry financial and reputational consequences
How does GIA® screen for Psychoactive Substance Abuse in skilled nursing facilities?
GIA® meets the patient by video, voice, or landline — wherever they are in the skilled nursing facilitie environment. The screening conversation takes 40 seconds and feels like a natural check-in, not a clinical assessment.
During the conversation, GIA® analyzes over 2,500 speech biomarkers — including vocal tremor, articulatory precision, prosodic patterns, and cognitive load indicators — alongside 436 visual data points from facial micro-expressions and body movement during video sessions.
Results are delivered to the clinician in under 2 minutes. Four data types write back to the EHR automatically: structured screening results with ICD-10 codes, clinician-ready medical notes, a full timestamped transcript, and the recorded patient video. The clinician reviews and submits — the human is always in the loop.
Psychoactive Substance Abuse in skilled nursing facilities: the numbers.
The screening challenge
Substance use disorder presents atypically across encounters: patients may attribute symptoms to medical or psychological causes, may underreport use due to stigma, may not connect functional impairment to use, and may not have insight into the severity of dependence. Standard structured screeners (AUDIT, AUDIT-C, DAST-10, NIDA Quick Screen) require the clinician to ask, the patient to disclose, and both to spend time within an already over-allocated visit envelope. The 72.7% treatment-receipt gap measured by SAMHSA 2022 reflects the cumulative effect of all stages from detection through specialty referral. GIA® analyzes 2,500+ speech biomarkers from a 40-second natural conversation; the underlying peer-reviewed research reports AUC 0.845 for substance use disorder detection, supporting an additional screening modality that does not depend on patient disclosure or structured instrument administration. Documentation supports billing accuracy for CPT 96127 brief emotional/behavioral assessment, CPT 99408 / 99409 SBIRT codes where applicable, and E/M coding; coding decisions remain with the clinical documentation and coding team.
What compliance requirements does this address?
MDS 3.0 Section C (Cognitive Patterns) and Section D (Mood) require documented screening. CMS F-Tag 605 requires psychotropic medication monitoring.
GIA® produces structured documentation automatically — screening results with ICD-10 codes, clinician-ready medical notes, full timestamped transcripts, and recorded patient video — all written back to the EHR in real time and available for clinical, billing, and compliance review.
Psychoactive Substance Abuse screening in skilled nursing facilities
How is Psychoactive Substance Abuse screened in skilled nursing facilities?
GIA® screens for Psychoactive Substance Abuse through a single conversational interaction lasting 40 seconds. She analyzes over 2,500 speech biomarkers using Voice AI, Computer Vision, and Speech Biomarkers. GIA® conducts screening conversations at the bedside, in the activity room, or by landline from the resident’s room — fitting naturally into existing daily routines without adding to nursing workload. Results are delivered to the clinician in under 2 minutes.
Does Psychoactive Substance Abuse screening require additional staff?
No. GIA® conducts the screening conversation independently — zero additional clinical staff required during the interaction. Licensed nurses manage 15-30 residents per shift. CNAs handle direct care for 8-12 residents. Time for proactive screening is virtually nonexistent. The clinician reviews the results in under 2 minutes.
What is the accuracy of Psychoactive Substance Abuse screening?
Psychoactive Substance Abuse screening accuracy: AUC 0.845. The platform is peer-reviewed across 19 published studies and trained on 12.3 million longitudinal PAC/LTC patient records and 27 billion clinical events.
How does GIA® screen for substance use disorders?
GIA® analyzes 2,500+ speech biomarkers — including articulation rate, vocal stability, prosodic patterns, and processing-speed markers associated with substance use — from a natural conversation lasting 40 seconds. Peer-reviewed biomarker accuracy for substance use disorder detection is AUC 0.845. Results write back to the EHR with structured notes for clinician review. A clinician reviews and approves every result before it enters the clinical record. Positive speech-biomarker signal supports structured follow-up screening (AUDIT, DAST-10, NIDA Quick Screen, TAPS) and SBIRT-aligned care planning.
Why is substance use disorder so frequently undertreated?
SAMHSA’s 2022 National Survey on Drug Use and Health found that 72.7% of US adults aged 12+ with a past-year substance use disorder — approximately 35.4 million of 48.7 million affected — did not receive any treatment in 2022. The gap reflects barriers at every stage: detection-stage barriers (under-recognition in primary care, atypical presentations), patient-side barriers (stigma, denial, low insight, financial cost), and system-side barriers (limited specialty referral capacity). Standard structured screeners require clinician time that competes with other guideline-recommended care — Porter et al. (J Gen Intern Med 2023) estimated 26.7 hours per day would be required for full guideline delivery.
How does GIA® support SBIRT and substance use screening billing?
CPT 99408 covers structured alcohol and/or substance use screening and brief intervention services (15–30 minutes total time); CPT 99409 covers the same services greater than 30 minutes. CPT 96127 (brief emotional/behavioral assessment with scoring and documentation, per standardized instrument) may apply to structured behavioral health screening. GIA® writes structured speech-biomarker screening results, ICD-10 codes, clinician-ready medical notes, and a full timestamped transcript to the EHR for clinician review. Documentation supports billing accuracy; coding decisions remain with the clinical documentation and coding team.
Does GIA® diagnose substance use disorder?
No. GIA® screens — she does not diagnose. She surfaces structured risk signals from speech biomarker analysis for clinician review. The clinician applies clinical judgment, reviews substance use history, administers structured assessment instruments (AUDIT, DAST-10, NIDA Quick Screen, TAPS) where indicated, evaluates severity criteria, considers laboratory and urine drug screen results, and makes any diagnostic determination including the differential among alcohol use disorder, opioid use disorder, stimulant use disorder, and other substance categories. GIA® is a clinical decision support tool with mandatory clinician-in-the-loop review on every result.
Does GIA® differentiate between specific substances?
The peer-reviewed speech biomarker research underlying GIA® for substance use disorder detection reports AUC 0.845 across the substance use validation set. Differentiation among specific substance categories — alcohol, opioids, stimulants, cannabis, sedatives — is a clinical determination requiring history, substance-specific assessment instruments, urine drug screening where indicated, and clinical interview. GIA® surfaces structured speech-biomarker signal that the clinician interprets in the broader clinical context.
Psychoactive Substance Abuse screening in other care settings
Other conditions screened in skilled nursing facilities
The Operator's Guide to Multimodal Clinical AI
What administrators, DONs, and regional operators need to know before evaluating clinical AI platforms. Covers EHR integration, staffing impact, reimbursement codes, and deployment timelines.
See GIA® screen for Psychoactive Substance Abuse live
40 seconds. 60-second results. Zero staff time.